Description

Carbamic Acid, n-(2,3-Dihydro-2-Oxo-5-Phenyl-1H-1,4-Benzodiazepin-3-Yl)-, Phenylmethyl Ester is a high-purity, advanced pharmaceutical intermediate of significant commercial and research interest. This compound is valued for its role as a key synthetic precursor in the development of active pharmaceutical ingredients (APIs), particularly within the benzodiazepine class. It is primarily sought by manufacturers and R&D laboratories in the pharmaceutical and fine chemical sectors for process development and scale-up activities.

Application

• Pharmaceutical Intermediate: A critical building block in the multi-step synthesis of novel benzodiazepine-based therapeutic agents.
• Active Pharmaceutical Ingredient (API) Development: Used in research and development for creating new candidate drug molecules targeting the central nervous system.
• Process Chemistry & Scale-Up: Serves as a standardized intermediate for optimizing synthetic routes and scaling production from laboratory to pilot plant and commercial manufacturing.
• Reference Standard: Employed as a high-purity analytical standard for quality control and method validation in pharmaceutical analysis.
• Chemical Research: Utilized in academic and industrial research to explore new chemical transformations and the structure-activity relationships of benzodiazepine derivatives.

Basic Information

Product Name	Carbamic Acid, n-(2,3-Dihydro-2-Oxo-5-Phenyl-1H-1,4-Benzodiazepin-3-Yl)-, Phenylmethyl Ester
CAS No.	108895-98-3
Molecular Formula	C23H19N3O3
Molecular Weight	385.42 g/mol
Synonyms	3-[(Benzyloxycarbonyl)amino]-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-(N-Carbobenzyloxyamino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-(Cbz-Amino)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-Phenyl-3-[(phenylmethoxy)carbonyl]amino-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-(N-CBZ-Amino)-5-phenyl-1,4-benzodiazepin-2-one; CBZ-Protected 3-Amino-5-phenyl-1,4-benzodiazepin-2-one; Z-3-Amino-5-phenyl-1,4-benzodiazepin-2-one
EINECS	Contact for details

Quality Control

Our production of this pharmaceutical intermediate adheres to stringent quality management systems. Every batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency. Certificates of Analysis (COA) detailing specifications such as assay, related substances, and residual solvents are provided with each shipment. We support compliance with cGMP guidelines for advanced intermediates and can tailor specifications to meet specific project requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). This product is light-sensitive (store away from light).

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Single Maximum Impurity	≤ 0.5%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.